(Circulation. 2000;101:624.)
© 2000 American Heart Association, Inc.
Clinical Investigation and Reports |
From the Division of Cardiology (Y.Y., M.H., T.K., Y.I., M.A., H.S.), First Department of Internal Medicine, University of Nagoya School of Medicine, Nagoya; Cardiovascular Center (T.Y., Y.M., M.T., M.O., J.T.), Aichi Prefectural Owari Hospital, Ichinomiya; and the Cardiovascular Center (Y.T., N.T., H.H., T.I.), Nagoya Dai-ni Red Cross Hospital, Nagoya, Japan.
Correspondence to Yukihiko Yoshida, MD, Division of Cardiology, First Department of Internal Medicine, University of Nagoya School of Medicine, 65 Tsurumai, Showa-ku, Nagoya 466-8550, Japan. E-mail ykyoshi{at}wb3.so-net.ne.jp
BackgroundIntracellular calcium overload is believed to play an important role in development of reperfusion arrhythmias. Dipyridamole, an inhibitor of cellular uptake of adenosine, may prevent or terminate reperfusion arrhythmias by reducing intracellular calcium overload.
Methods and ResultsFirst, we tested for a preventive effect of dipyridamole. Sixty-one patients who underwent primary PTCA for treatment of acute anterior wall myocardial infarction were enrolled in this prospective study. Patients were divided into dipyridamole (DP) and nondipyridamole (non-DP) groups. The 2 groups had similar baseline characteristics. In the DP group, dipyridamole 0.5 mg/kg was infused intravenously for 3 minutes immediately before reperfusion during primary PTCA. Arrhythmias after reperfusion were analyzed from continuous ECG recordings. None of the patients in the DP group (n=23) had accelerated idioventricular rhythms (AIVR) or ventricular tachycardia (VT). In contrast, 7 (18.4%) had AIVR and 3 (7.9%) had VT in the non-DP group (n=38; P<0.01). Second, we tested for a termination effect of dipyridamole. Dipyridamole 0.5 mg/kg was infused intravenously while continuous ECG recordings were obtained in 9 patients who had either sustained AIVR (n=7) or sustained VT (n=2) after reperfusion of occluded coronary artery. Arrhythmias were terminated in all patients.
ConclusionsThese results indicate that administration of dipyridamole can prevent and terminate reperfusion arrhythmias such as AIVR and VT. cAMP-mediated triggered activity may, at least in part, be responsible for reperfusion-induced AIVR and VT.
Key Words: adenosine arrhythmia myocardial infarction reperfusion
This article has been cited by other articles:
![]() |
M. Kato, K. Dote, S. Sasaki, H. Takemoto, S. Habara, and D. Hasegawa Intracoronary Verapamil Rapidly Terminates Reperfusion Tachyarrhythmias in Acute Myocardial Infarction Chest, September 1, 2004; 126(3): 702 - 708. [Abstract] [Full Text] [PDF] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2000 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |